This review considers whether orally consumed beta-glucans could complement adoptive T-cell therapies by activating innate immune cells and making the tumor microenvironment less suppressive. It summarizes absorption and trafficking research, studies in healthy participants and cancer patients, and mouse tumor models. The proposed combination is a research hypothesis supported mainly by mechanistic and preclinical evidence, not an established cancer treatment or proof for a specific Aureobasidium product.
A review of oral beta-glucans as possible adjuncts to adoptive T-cell cancer therapy.
Innate-immune activation may help create a tumor environment that is more supportive of T-cell activity.
The combination remains a research proposal based largely on mechanistic and animal evidence, not an established treatment.
AI-generated summary for accessibility. Always refer to the original paper.
de Graaff P., Govers C., Wichers H., Debets R.. Consumption of β-glucans to spice up T cell treatment of tumors: a review. Expert Opinion on Biological Therapy. 2018. DOI: 10.1080/14712598.2018.1523392.
For scientific reference only. Not medical advice. Consult a qualified healthcare professional. See our Medical Disclaimer.